gnf-2

GNF-2 is a highly selective non-ATP competitive inhibitor of Bcr-Abl.

GNF-2-deg is a PROTAC degrader that targets the envelope protein of the dengue virus (DENV E protein), achieving a DC50 of 0.83 μM. It inhibits viral entry by preventing membrane fusion mediated by the E protein and demonstrates antiviral activity against DENV 2 through protein degradation, with an EC90 of 3.5 μM. Additionally, GNF-2-deg shows antiviral efficacy against ZIKV, JEV, WNV, and YFV, with EC90 values ranging from 1.96 to 7.79 μM.

GNF-5 is a specific non-ATP competitive inhibitor of Bcr-Abl (IC50: 0.22±0.1 uM, Wild-type Abl). It is an analog of GNF-2 with improved pharmacokinetic properties.

GNF2133 is an effective and selective inhibitor of DYRK1A with IC50s of 6.2 nM. GNF2133 can be used in studies about type 1 diabetes.

GNF2133 hydrochloride is a selective, effective, and orally active DYRK1A inhibitor, able to act on DYRK1A (IC50: 0.0062 μM) and GSK3β (IC50> 50 μM); GNF2133 hydrochloride showed good proliferative ability and efficacy in rat and human primary β cells. GNF2133 hydrochloride significantly improved glucose processing ability and increased insulin secretion. GNF2133 hydrochloride has the potential to study type 1 diabetes.

GNF-PF-3777 (8-Nitrotryptanthrin) is a potent inhibitor of human indoleamine 2,3-dioxygenase 2 (hIDO2) with a Ki of 0.97 μM.

GNF5-amido-Me, the moiety based on GNF5 (ABL inhibitor),binds through a linker to the IAP ligand forming SNIPER[1].